Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 365-371

  Strouse, John J ^a   Heeney, Matthew M ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Children; Efficacy; Hydroxyurea; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ABDOMINAL PAIN; ACUTE CHEST SYNDROME; AFRICA; ANEMIA; BACTEREMIA; BLOOD CELL COUNT; CHROMOSOME BREAKAGE; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; GENOTOXICITY; GENOTYPE; HUMAN; JAUNDICE; LEUKOCYTE DIFFERENTIAL COUNT; LIVER DYSFUNCTION; MAXIMUM TOLERATED DOSE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETICULOCYTE COUNT; RETICULOCYTOPENIA; REVIEW; SEPSIS; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; DISEASE MANAGEMENT; HUMANS; HYDROXYUREA; TREATMENT OUTCOME;

EID: 84862254136     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24178     Document Type: Review

References (47)

1. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine (Baltimore) 1996; 75: 300- 326.
2. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37- 47.
3. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002; 99: 2297- 2303.
4. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002; 116: 436- 444.
5. Fetal hemoglobin induction. In: National Institutes of Health National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources; The management of sickle cell disease: NIH publication no. 02-2117. Bethesda, MD: 2002; p 161- 166.
6. Segal J, Strouse J, Beach M, et al. Hydroxyurea for the treatment of sickle cell disease evidence report (publication no. 08-e007). Washington, D.C.: Agency for Healthcare Research and Quality; 2008.
7. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008; 122: 1332- 1342.
8. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health consensus development conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932- 938.
9. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377: 1663- 1672.
10. Wang W, Brugnara C, Snyder C, et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial. Br J Haematol 2011; 152: 771- 776.
11. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (switch): A phase 3 randomized clinical trial for treatment of children with sickle cell anemia, previous stroke, and iron overload. ASH Ann Meeting Abstr 2010; 116: 844.
12. Hankins JS, Helton KJ, McCarville MB, et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 2008; 50: 293- 297.
13. Lefevre N, Dufour D, Gulbis B, et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 2008; 111: 963- 964.
14. Greenway A, Ware RE, Thornburg CD. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol 2011; 86: 357- 361.
15. Gordeuk VR, Campbell A, Rana S, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 114: 4639- 4644.
16. Lobo C, Hankins JS, Moura P, et al. Hydroxyurea therapy reduces mortality among children with sickle cell disease. ASH Ann Meet Abstr 2010; 116: 843.
17. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LASHS). Blood 2010; 115: 2354- 2363.
18. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008; 93: 988- 993.
19. Lukusa AK, Vermylen C, Vanabelle B, et al. Bone marrow transplantation or hydroxyurea for sickle cell anemia: Long-term effects on semen variables and hormone profiles. Pediatr Hematol Oncol 2009; 26: 186- 194.
20. Lukusa AK, Vermylen C. Use of hydroxyurea from childhood to adult age in sickle cell disease: Semen analysis. Haematologica 2008; 93: e67 discussion e68.
21. Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc 2009; 101: 1046- 1051.
22. Flanagan JM, Howard TA, Mortier N, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 2010; 698: 38- 42.
23. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opin Hematol 2011; 18: 158- 165.
24. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652- 656.
25. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am 2008; 55: 483- 501.
26. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115: 5300- 5311.
27. Mueller BU. When should hydroxyurea be used for children with sickle cell disease? Pediatrics 2008; 122: 1365- 1366.
28. Ryan KM, Heeney MM. Use of hydroxyurea in pediatric patients with sickle cell disease. Boston: 2004; (Accessed June 1, 2011, at .).
29. Lane PA, Buchanan GR, Hutter JJ, et al., Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications. 2001. (Accessed June 1, 2011, at .).
30. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric hydroxyurea group. Blood 1999; 94: 1550- 1554.
31. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001; 139: 790- 796.
32. Thornburg CD, Dixon N, Burgett S, et al. Efficacy of hydroxyurea to prevent organ damage in young children with sickle cell anemia. Blood 2007; 110: 3386.
33. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103: 2039- 2045.
34. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial doppler flow velocities in children with sickle cell anemia. Blood 2007; 110: 1043- 1047.
35. Heeney MM, Whorton MR, Howard TA, et al. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004; 26: 179- 184.
36. Harrod VL, Howard T, Abboud MR, et al. Chemical and functional analysis of generic hydroxyurea formulations. Pediatr Hematol Oncol 2008; 25: 423- 429.
37. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996; 88: 4701- 4710.
38. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79: 2555- 2565.
39. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999; 94: 3022- 3026.
40. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004; 145: 346- 352.
41. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975; 13: 10- 24.
42. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86: 273- 277.
43. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116: 687- 692.
44. McGann PT, Howard TA, Flanagan JM, et al. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol 2011; 154: 134- 140.
45. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009; 62- 69.
46. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331- 4336.
47. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115: 3447- 3452.